Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PCVX
SellHot AirVaxcyte, Inc. · Healthcare · United States · $8.9B · Avg Vol: $56M/d
COMPANY DESCRIPTION
Vaxcyte, Inc. is a clinical-stage biotechnology company developing novel vaccines to prevent or treat infectious diseases. Its lead programs target pneumococcal disease and other bacterial infections, utilizing its proprietary cell-free protein synthesis platform. The company's competitive differentiation lies in its innovative platform technology, which aims to produce more effective and broader-spectrum vaccines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 87.1M | — |
| EPS | -3.44 | -4.14 | -3.80 | -5.63 | — | -7.63 | -8.20 | -7.22 | — |
| Shares | 79.5M | 95.4M | 124.9M | 131.1M | +64.9% | 148.8M | — | — | — |
| Debt | 17.9M | 29.2M | 71.1M | 117.5M | 87.1% | 115.4M | — | — | — |
| Equity | 953.6M | 1.2B | 3.3B | 2.7B | 41.2% | — | — | — | — |
| Op CF | -170.6M | -296.8M | -452.6M | -655.6M | — | -881.2M | — | — | — |
| Inv CF | 74.6M | -773.3M | -2.0B | 437.4M | — | — | — | — | — |
| Fin CF | 861.5M | 639.8M | 2.4B | 2.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PCVX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PCVX | Vaxcyte, Inc.(you) | $8.9B | 28 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 25 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 32 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 26 | Sell |
| CYTK | Cytokinetics, Incorporated | $10.0B | 22 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%